Alzheimer’s disease (AD) is among the most significant health care burdens. Disappointing results from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with early-stage suggest that research in the preclinical stage of AD is necessary to define an optimal therapeutic success window. We review the justification for conducting trials in the preclinical stage and highlight novel ethical challenges that arise and are related to determining appropriate risk-benefit ratios and disclosing individuals’ biomarker status.
from Dementia Big http://ift.tt/1Mjjup9
via Stopping Dementia
from WordPress http://ift.tt/1UwOWH5
via alcoholic dementia
http://ift.tt/1RjulH7
No comments:
Post a Comment